Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNA02-48 + tetanus toxoid is a combination vaccine comprising SNA02-48 and tetanus toxoid. Tetanus toxoid is an inactivated form of tetanus toxin produced from *Clostridium tetani*, which is detoxified with formaldehyde. It stimulates the immune system to produce antibodies against tetanus, conferring protective immunity. Tetanus toxoid is a legacy, clinically effective vaccine and is often used as a carrier protein in conjugate vaccine formulations for small molecules, peptides, or polysaccharides. The mechanism of action is through active immunization by eliciting a humoral immune response without causing the pathogenic effects of the toxin. SNA02-48 is presumed to be a novel or experimental antigen or conjugate, but no detailed public data are available on its composition or biological effects. The combination likely serves as a vaccine candidate in which tetanus toxoid may act both as an immunogen and possibly a carrier protein, with the goal of inducing protective immunity either to tetanus alone or to additional targets via SNA02-48[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SNA02-48 + tetanus toxoid.